Vectibix : FDA Approves for Colorectal Cancer

Vectibix : FDA Approves for Colorectal Cancer

The Food and Drug Administration (FDA) approved Vectibix (panitumumab) for the treatment of patients with colorectal cancer that has metastasized (spread to other parts of the body) following standard chemotherapy. Vectibix, a monoclonal antibody that binds to a protein called epidermal growth factor receptor or EGFR on some cancer cells, received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor.

In the United States, it is estimated that 150,000 new cases of colon cancer will be diagnosed and 55,000 deaths will occur from colon and rectal cancer in 2006. Approximately 70 percent of all colorectal carcinomas test positive for EGFR.

“Colorectal cancer is the third most common cancer and the third leading cause of cancer mortality in the United States,” said Dr. Steven Galson, director of FDA’s Center for Drug Evaluation and Research. “This approval adds a treatment option for patients with an advanced stage of a disease that can be life-threatening.”

FDA approved Vectibix on the basis of the results of a randomized, controlled clinical trial of 463 patients with metastatic cancer of the colon and the rectum after undergoing treatment with chemotherapy drugs, fluoropyrimidine, oxaliplatin and irinotecan.

The mean time to disease progression or death in patients receiving Vectibix was 96 days versus 60 days in patients receiving the best standard supportive care. In addition, 8 percent of the patients on Vectibix experienced a tumor shrinkage that in some cases exceeded 50 percent of the pre-treatment size of the tumor. Both study groups showed similar overall survival.

Under the accelerated approval program, drugs for serious and life-threatening diseases can be made available earlier in the development process if a promising effect of the drug is observed. As part of the approval, the manufacturer of Vectibix committed to conduct a postmarketing trial to show whether the drug improves patients’ survival in patients with fewer prior chemotherapies.

The most serious adverse events in the studies of Vectibix included pulmonary fibrosis, severe skin rash complicated by infections, infusion reactions, abdominal pain, nausea, vomiting and constipation. The most common adverse events associated with the drug included skin rash, fatigue, abdominal pain, nausea, and diarrhea.

Vectibix is manufactured by Amgen Inc. in Thousand Oaks, California.

You may also be interested in . . .

Comments

Post new comment

Related health news

  • Google Launched Google Health to Store and Manage Medical History - After a year and half of development, Google began offering online personal health records to the public on Monday.
  • Effective OTC Drug for Seasonal Allergy: Zyrtec-D, Less Drowsiness - Allergies of several types can occur in kids and teens. Environmental allergies (to dust mites, for example), seasonal allergies (such as hay fever), drug allergies (reactions to specific medications or drugs), food allergies (such as to nuts), and allergies to toxins (bee stings, for example) are the common conditions people usually refer to as allergies.
  • Medicinal Error Costs Huge - Traditionally, errors are attributed to mistakes made by individuals who may be penalized for the mistakes. The usual approach to correct the errors is to create new rules with additional checking steps in the system, aiming to prevent further errors.
  • Stomach Surgery May Change Drug Absrorption for Obese Individual - Overweight and obesity are rising medical problems of pandemic proportions. There are many detrimental health effects of obesity: heart disease, diabetes, many types of cancer, asthma, obstructive sleep apnea, chronic musculoskeletal problems, etc. There is also a clear effect of obesity on mortality, though this is not so clear for overweight.
  • Viagra May Worsen Sleep-Related Breathing Disorder - Male impotence or erectile dysfunction (ED) or is defined as the inability of a man to achieve and maintain an erection sufficient for mutually satisfactory intercourse with his partner.
  • FDA Warned Not to Buy Drugs from Various Canadian Websites - A leader of the Food and Drug Administration's drug-safety office has told Congress that the agency and its once-vaunted Center for Drug Evaluation and Research are “broken.” The FDA is currently the object of several investigations, including one initiated at its own request.
  • Where Drug Absorbs / Delivers? - Absorption is the process by which the drug enters into the systemic circulation from the site of administration (except intravenous or intra-arterial routes) through biological barrier. In case of intravenous or intra-arterial administration the drug is not absorbed and it enters into the circulation directly.